Vera Therapeutics Expands Portfolio with VT-109 Acquisition
Deal News | Jan 13, 2025 | Globenewswire
Vera Therapeutics has announced an exclusive license agreement with Stanford University to acquire global rights to a novel, next-generation dual BAFF/APRIL inhibitor, VT-109, which is positioned to provide significant therapeutic potential across a variety of B cell-mediated diseases. The agreement supports Vera's strategy of leadership in B cell modulation, a key component in treating autoimmune diseases. The acquisition involves undisclosed upfront and milestone payments, furthering the company's commitment to advancing treatments that alter the standard care for conditions such as IgA nephropathy and lupus nephritis. Vera Therapeutics continues to retain global development and commercial rights to its primary product candidates, atacicept and MAU868, adding VT-109 to its expanding pipeline of therapeutics aimed at combatting serious immunological illnesses.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Vera Therapeutics is based in California, USA, and the acquisition agreement is with Stanford University, another American institution.
Industry
- Biotechnology – The article centers around Vera Therapeutics, a biotech company developing innovative therapies for immunological diseases, particularly focusing on B cell-related treatments.
- Pharmaceuticals – The industry involves drug development and commercialization, relevant to Vera's acquisition and development of therapeutic proteins and antibodies like VT-109.
Financials
- Undisclosed – The agreement involves undisclosed upfront and milestone payments for the acquisition of global rights to VT-109.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vera Therapeutics, Inc. | Acquirer | Company | A late clinical-stage biotechnology company focused on developing therapies for serious immunological diseases. |
| Stanford University | Vendor | Educational Institution | The provider of the exclusive license for the novel therapeutic protein VT-109. |
| VT-109 | Therapeutic Asset | Product | A novel, next-generation fusion protein with potential therapeutic applications across a spectrum of B cell-mediated diseases. |
| Marshall Fordyce, M.D. | CEO | Person | Founder and CEO of Vera Therapeutics, involved in the acquisition strategy. |